Member Info for Leisurely

Hadn’t noticed till you mentioned it. Is certainly is not typical. The 2.4m buys over 4 trades yesterday and the 4.9m sells today over 2 trades definitely stand out. Given the pricing they appear to be correctly categorised but / sell.

The rns is good news. If they’re successful on the refinancing without having to set a high coupon then the five year stable financing should boost the share significantly. Roll on 5th November (which I think is when everything is done and dusted from what I could tell).

Good trajectory in rns. Cash balances $1.5m higher than July but still $4.5m lower than same time last year. Production volumes rising which should be very beneficial when market recovers for gas (which it will).

Well, if no one is really buying or selling the price won’t move. This is fairly illiquid. Likely we’ll find a much sharper move when results announced at end of November especially given this will be giving a dividend and positive outlook.

Chrome: the avg price for year to sep 2019 was 162/t and to sep 2020 was 140/t. To sep 2019 produce 1.29mt (higher this year). So this year we’d have a revenue hit of -22 x 1.29m = $-28.30m revenue than last year for the first 1.29mt. But this year we produced a bit more and we still make a profit at 140/t so net profit impact is slightly less than say $-28m (ignoring costs of production)

Pgm: the avg price for year to sep 2019 was $1081/oz and to sep 2020 $1704/oz. To sep 2019 produced 139.7koz (higher this year). So this year we have a revenue hit of +623 x 139.7koz = +$87m revenue compared with last year for the first 139.7oz. But this year we produced a bit more so let’s say profit impact of $+90m.

Costs: Costs are mostly in south African rand whereas revenue and profit reporting is based on dollars. The average fx rate dropped from about 14.4 to 16.4 reducing costs in dollar terms by about 13%. This will also have improved the bottom line and absorbed some or all of increased localised costs.

So we should be targeting at least $60m increase in headline profits over last year. Haven’t tracked how much increased investment may reduce this. And next year ,if expected mid estimate production increases materialise and the avg price carries over then revenue up another $52m on what is a profitable business (even chrome).

It’s looking promising.

Very pleased with those results!

Considering the environment at the moment these are great q3 results with a 30% increase in net cash from q2. Trajectory is really positive.

Blue, the main point is the result did offer better than the placebo; and more importantly, no matter how cr*p people thinks the results were , they were as good as the current market competitors but without the side effects. That means the market is up for grabs ... 2.4bn in us alone.

Thank god the market has finally closed ! What a cr*p day.

To be honest, there are a lot of ppl (me included) who invested at around 40-45p. Can’t really blame them for realising a profit now and good for them. It’s only real once you bank it. Very confident when the results and presentation are fully digested this is going to go north rapidly.

Sorry. Wrong board!

To be honest, there are a lot of ppl (me included) who invested at around 40-45p. Can’t really blame them for realising a profit now and good for them. It’s only real once you bank it. Very confident when the results are fully digested this is going to go north rapidly.

I’m invested in this - quite heavily now given the share price increase over last two months. Not worried as the presentation gave context that this is potentially a commercial time bomb. I have bought quite a bit more at about 130 just now which I’ll trade as I can’t see things staying like this for more than a day or a couple of days. We’ll see.

Even if this dips it won’t be for long - see my earlier comment re presentation.

I originally said the results are ‘ok, certainly not great’. I’ve listened to the presentation on the website. Key adds are that the efficacy as as good as other drugs on the market but without the side effects; increases the market by a third as can cover its-m subtype; the us market in 2024 est 2.4bn which is an ‘underestimate’; already talking to ‘all the major players in the field’. So, whilst on the face of it the results don’t look exceptional they are good enough to have massive commercial implications. So I correct my original assessment - the results are great.

If you read the rns properly the results are just ok, certainly not great.

I’m very positive about the upcoming results.

However it’s important still to compare like with like. Due to two placings there has been 64% share dilution since December. So on a like for like basis, the December market cap (100p a share) would be about 60p today given the share dilution. So I’m guessing our market cap now is already 250% of that in December. Just estimating but seems logical to me.

Also, in the interview the CEO gave a few weeks ago I got the distinct impression he was downplaying COVID results this year. Did anyone else feel this?

This rns is good news. I just don’t get why there is no expression of pleasure on the outcome within the rns. I’ve re-read is a number of times just in case I’ve misinterpreted something.

Unfortunately , LEK appears to have deteriorating cash flow issues.

I think they’ve only ever said they are targeting end of year for refinancing. May do it before Oct 31 but that’s date is irrelevant.